

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
建石良介	V 肝・胆・膵疾患 8. 肝癌	門脇孝、小室一成、宮地良樹	日常診療に活かす診療ガイドライン UP-TO-DATA 2018-2019	メディカルレビュー社	東京	2018	343-348

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, <u>Koike K</u>	Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.	J Gastroenterol	[Epub]		2019
Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, Eguchi H, Moriya K, <u>Koike K</u> , Mimori K, Mori M, Katayama Y, Nakayama KI	Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis.	J Exp Med	216(4)	950-965	2019
Nakagomi R, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, <u>Koike K</u>	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment.	J Gastroenterol Hepatol	34(5)	921-928	2019
Nakatsuka T, Soroida Y, Nakagawa H, Shindo T, Sato M, Soma K, Nakagomi R, Kobayashi T, Endo M, Hikita H, Sato M, Gotoh H, Iwai T, Yasui M, Shinozaki-Ushiku A, Shiraga K, Asakai	Identification of liver fibrosis using the hepatic vein waveform in patients with Fontan circulation.	Hepatol Res	49(3)	304-313	2019

H, Hirata Y, Fukayama M, Ikeda H, Yatomi Y, Tateishi R, Inuzuka R, <u>Koike K</u>					
Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, <u>Koike K</u>	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.	J Hepatol	70(1)	78-86	2019
Fujiwara H, Tateishi K, Kato H, Nakatsuka T, Yamamoto K, Tanaka Y, Ijichi H, Takahara N, Mizuno S, Kogure H, Matsubara S, Nakai Y, <u>Koike K</u>	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.	Cancer Sci	109(11)	3602-3610	2018
Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, <u>Koike K</u>	Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.	Cancers (Basel)	10(11)		2018
Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, <u>Koike K</u>	Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis.	World J Gastroenterol	24(32)	3617-3625	2018
Sawai H, Nishida N, Khor SS, Honda M, Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, <u>Koike K</u> , Kondo Y, Yatsushashi H, Nagaoka S, Taketomi A, Fukai M, Kurosaki M, Izumi N, Kang JH, Murata K, Hino K, Nishina S, Matsumoto A, Tanaka E, Sakamoto N, Ogawa K, Yamamoto K, Tamori A, Yokosuka O, Kanda T, Sakaida I, Itoh Y, Eguchi Y, Oeda S, Mochida S, Yuen MF, Seto WK, Poovorawan Y, Posuwan N, Mizokami M, Tokunaga K	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma.	Sci Rep	8(1)	7958	2018
Sekiba K, Otsuka M, Ohno M, Kishikawa T, Yamagami M, Suzuki	DHX9 regulates production of hepatitis B virus-derived circular RNA and viral	Oncotarget	9(30)	20953-20964	2018

T, Ishibashi R, Seimiya T, Tanaka E, <u>Koike K</u>	protein levels.				
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, <u>Koike K</u>	Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA.	World J Gastroenterol	24(21)	2261-2268	2018
Shimizu K, Soroida Y, Sato M, Hikita H, Kobayashi T, Endo M, Sato M, Gotoh H, Iwai T, Tateishi R, <u>Koike K</u> , Yatomi Y, Ikeda H.	Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.	Sci Rep	8(1)	7845	2018
Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, <u>Koike K</u> , Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H	Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.	PLoS One	13(10)	e0204772	2018
Tanaka Y, Tateishi R, <u>Koike K</u>	Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.	Int J Mol Sci	19(10)		2018
Uchino K, Tateishi R, Nakagomi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shibahara J, Shiina S, <u>Koike K</u>	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation.	PLoS One	13(7)	e0200943	2018
Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, <u>Izumi N</u> , Kadoya M, Sakamoto M, Nakashima O, Maysuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M	Liver Cancer Study Group of Japan. Liver resection for multiple hepatocellular carcinomas: A Japanese nationwide survey.	Ann Surg	[Epub]		2019
Kobayashi M, Kudo M, <u>Izumi N</u> , Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M,	Cost-effective analysis of Lenvatinib treatment for patients with unresectable hepatocellular carcinoma	J Gastroenterol	[Epub]		2019

Ikeda S.	(uHCC) compared with sorafenib in Japan.				
Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, <u>Izumi N</u> , Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.	J Gastroenterol	[Epub]		2019
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Shimizu T, Watakabe K, Enomoto N, <u>Izumi N</u> .	Real-life experience of lusuthrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.	PLoS One	14(2)	e0211122	2019
Yasui Y, Abe T, Kurosaki M, Matsunaga K, Higuchi M, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Takaura K, Masugi Y, Nakanishi H, Tsuchiya K, Takahashi Y, Itakura J, Sakurai U, Hashiguchi A, Sakamoto M, <u>Izumi N</u> .	Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C.	Hepatol Res	49(1)	33-41	2019
Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S, Uchida Y, Sohda T, Suzuki H, Yoshida H, Kusakabe A, Tamada T, Kobashi H, Mitsuda A, Kondo M, Shigeno M, Ide Y, Morita A, Kitamura T, Abe T, <u>Izumi N</u>	Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.	Hepatol Res.	49(3)	264-270	2019

Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, <u>Izumi N</u> , Imawari M.	A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.	J Gastroenterol.	54(2)	171-181	2019
Suda G, Kurosaki M, Itakura J, <u>Izumi N</u> , Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.	J Gastroenterol.	54(1)	78-86	2019
Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, <u>Izumi N</u> .	Prediction of hepatocellular carcinoma after sustained virologic responses using magnetic resonance elastography.	Clin Gastroenterol Hepatol	[Epub]		2018
Yasui Y, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Kubota Y, Higuchi M, Takaura K, Tsuchiya K, Nakanishi H, Takahashi Y, Itakura J, Enomoto N, <u>Izumi N</u> .	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.	Hepatol Res.	48(13)	1131-1139	2018
<u>Izumi N</u> , Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G,	Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.	Hepatol Int.	12(4)	356-367	2018

Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.					
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Enomoto N, <u>Izumi N.</u>	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.	PLoS One.	13(6)	e0198812	2018
Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, <u>Izumi N.</u>	Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method.	Hepatol Res.	48(10)	821-828	2018
Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y, Nakata R, Goto T, Takehiro A, Kimura H, Mitsuda A, Kawanami C, Uchida Y, Ogawa C, Kusakabe A, Narita R, Ide Y, Abe T, Tsuji K, Kitamura T, Okada K, Sohda T, Shigeno M, Satou T, <u>Izumi N.</u>	Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.	PLoS One.	13(4)	e0194704	2018
Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, <u>Izumi N.</u>	Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.	J Gastroenterol.	53(10)	1142-1150	2018
Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, <u>Izumi N.</u> , Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan.	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort.	Ann Surg.	[Epub]		2018

Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, <u>Izumi N</u> .	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis.	Hepatol Res.	48(9)	746-756	2018
Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, Wang W, Kubota Y, Goto T, Komiyama Y, Higuchi M, Takaura K, Hayashi T, Takada H, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Himeno Y, <u>Izumi N</u> .	Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.	Hepatol Res.	48(6)	442-450	2018
Takayasu K, Arai S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, <u>Izumi N</u> , Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N.	Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤ 2 cm analysed with propensity score weighting.	Liver Int.	38(3)	484-493	2018
Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, <u>Izumi N</u> , Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y.	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.	Lancet Gastroenterol Hepatol.	3(1)	37-46	2018
Hidaka H, Kokubu S, Sato T, Katsushima S, <u>Izumi N</u> , Igura T, Asahara S, Notsumata K, Osaki Y, Tsuji K, Kawanaka H, Akahoshi T, Hirota S, Matsutani S	NPB-06 study group. Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial.	Hepatol Res.	48(3)	E107-E116	2018

Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, <u>Izumi N</u> , Okita K, Koike K.	Response criteria of tolvaptan for the treatment of hepatic edema.	J Gastroenterol	53(2)	258-268	2018
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, <u>Izumi N</u> , Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan.	Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey.	Hepatology	66(2)	510-517	2017
Hidaka H, Kokubu S, Sato T, Katsushima S, <u>Izumi N</u> , Igura T, Asahara S, Notsumata K, Osaki Y, Tsuji K, Kawanaka H, Akahoshi T, Hirota S, Matsutani S; NPB-06 study group.	Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial.	Hepatology Res.	48(3)	E107-E117	2018
Harding JJ, Watanabe T, El-Dika I, Nishida N, Abou-Alfa GK, <u>Kudo M</u>	2.5 “Gastrointestinal Malignancies”; 2.5.3 Hepatocellular carcinoma.	ESMO Handbook of Immuno-Oncology		191-202	2018
<u>Kudo M</u> , Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.	Lancet Gastroenterol Hepatol	3(1)	37-46	2018
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan	Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤ 2 cm analysed with propensity score weighting.	Liver Int	38(3)	484-493	2018
<u>Kudo M</u>	Lenvatinib may drastically change the treatment landscape of hepatocellular	Liver Cancer	7(1)	1-19	2018

	carcinoma.				
<u>Kudo M</u>	Combination cancer immunotherapy in hepatocellular carcinoma.	Liver Cancer	7(1)	20-27	2018
<u>Kudo M</u> , Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.	Lancet	391 (10126)	1163-1173	2018
Ikeda M, <u>Kudo M</u> , Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE Study Group	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.	J Gastroenterol	53(2)	281-290	2018
Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, <u>Kudo M</u>	Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.	Eur Radiol	28(5)	1986-1993	2018
<u>Kudo M</u> , Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S	Regional differences in efficacy, safety and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study.	Liver Cancer	7(2)	148-164	2018
Ikeda M, <u>Kudo M</u> , Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE Study Group	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.	J Gastroenterol	53(2)	281-290	2018
Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, <u>Kudo M</u>	Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation	Eur Radiol	28(5)	1986-1993	2018

	margin in the treatment of hepatocellular carcinoma.				
<u>Kudo M</u> , Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S	Regional differences in efficacy, safety and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study.	Liver Cancer	7(2)	148-164	2018
<u>Kudo M</u> , Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.	Lancet Gastroenterol Hepatol	3(6)	424-432	2018
Raoul JL, <u>Kudo M</u> , Finn RS, Edeline J, Reig M, Galle PR	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.	Cancer Treat Rev	68	16-24	2018
<u>Kudo M</u>	Cabozantinib as a second-line agent in advanced hepatocellular carcinoma.	Liver Cancer	7(2)	123-133	2018
<u>Kudo M</u>	Management of hepatocellular carcinoma in Japan as a world-leading model.	Liver Cancer	7(2)	134-147	2018
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, <u>Kudo M</u> , Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.	Brit J Cancer	119(1)	19-26	2018
Yen CJ, Muro K, Kim TW, <u>Kudo M</u> , Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC	Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials.	J Glob Oncol	4	1-12	2018

Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus, SW, Ma J, Siegel AB, Cheng AL, <u>Kudo M</u> , for the KEYNOTE-224 investigators	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.	Lancet Oncol	19(7)	940-952	2018
Nishida N, <u>Kudo M</u>	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.	Hepatol Res	48(8)	622-634	2018
Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, <u>Kudo M</u> , Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S	How to perform contrast-enhanced ultrasound (CEUS).	Ultrasound Int Open	4(1)	E2-15	2018
<u>Kudo M</u>	Proposal of primary endpoints for TACE combination trials with systemic therapy: Lessons learned from 5 negative trials and the positive TACTICS trial.	Liver Cancer	7(3)	225-234	2018
<u>Kudo M</u>	Extremely high objective response rate of Lenvatinib: Its clinical relevance and changing the treatment paradigm in hepatocellular	Liver Cancer	7(3)	215-224	2018

	carcinoma.				
<u>Kudo M</u>	Ramucirumab as second-line systemic therapy in hepatocellular carcinoma.	Liver Cancer	7(4)	305-311	2018
<u>Kudo M</u>	Systemic therapy for hepatocellular carcinoma: Latest advances.	Cancers	10(11)	E412	2018
Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, <u>Kudo M</u> , Kumada T, Roayaie S, Johnson PJ	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.	J Hepatol	69(6)	1284-1293	2018
Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, <u>Kudo M</u>	Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.	Antivir Ther	23(6)	513-521	2018
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, <u>Kudo M</u> , Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX	Corrigendum to “Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study”.	Eur J Cancer	100	135-136	2018
Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, <u>Kudo M</u> , Barr RG	Liver ultrasound elastography: An update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations.	Ultrasound Med Biol	44(12)	2419-2440	2018
Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.	Invest New Drugs	36(6)	1072-1084	2018

O, <u>Kudo M</u>					
Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, <u>Kudo M</u>	Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy.	Cancers	10(10)	E367	2018
Wada H, Eguchi H, Nagano H, <u>Kubo S</u> , Nakai T, Kaibori M, Hayashi M, Takemura S, Tanaka S, Nakata Y ⁴ , Matsui K, Ishizaki M, Hirokawa F, Komeda K, Uchiyama K, Kon M, Doki Y, Mori M	Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis.	Surg Today	48(1)	73-79	2018
Motoyama H, Tamori A, <u>Kubo S</u> , Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N	Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.	PLoS One	13(7)	E0194163	2018
Shinkawa H, Tanaka S, Takemura S, Ito T, Aota T, Koda M, Miyazaki T, Yamamoto T, <u>Kubo S</u>	Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C.	Annals of Gastroenterological Surgery	2(4)	319-326	2018
Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G, Ito T, Kawada N, Shibata T, <u>Kubo S</u>	Long-term prognostic factors after hepatic resection for hepatitis C virus-related hepatocellular carcinoma, with a special reference to viral status.	Liver Cancer	7(3)	261-276	2018
Tanaka S, Ueno M, Iida H, Kaibori M, Nomi T, Hirokawa F, Ikoma H, Nakai T, Eguchi H, <u>Kubo S</u>	Preoperative assessment of frailty predicts age-related events after hepatic resection: A prospective multicenter study.	Journal of Hepatobiliary Pancreatic Science	25(8)	373-387	2018
<u>Miyata H</u>	The effect of body weight in infants undergoing	The Journal of Thoracic and	157(8)	1132-1141	2019

	ventricular septal defect closure: A report from the Nationwide Japanese Congenital Surgical Database.	Cardiovascular Surgery			
<u>Miyata H</u>	Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database.	Annals of Surgery	[Epub]		2019
Kodera Y, Yoshida K, Kumamaru H, Kakeji Y, Hiki N, Etoh T, Honda M, <u>Miyata H</u> , Yamashita Y, Seto Y, Kitano S, Konno H	Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan.	Gastric Cancer	[Epub]		2019
Shoji S, Kohsaka S, Kumamaru H, Sawano M, Shiraishi Y, Ueda I, Nomura S, Suzuki M, Numasawa Y, Hayashida K, Yuasa S, <u>Miyata H</u> , Fukuda K	Stroke After Percutaneous Coronary Intervention in the Era of Transradial Intervention.	Circulation: Cardiovascular Interventions	11(12)	6761	2018
Sugimoto K, Hirata Y, Hirahara N, <u>Miyata H</u> , Suzuki T, Murakami A, Miyaji K, Takamoto S	Mid-term result of atrioventricular valve replacement in patients with a single ventricle.	Interactive Cardiovascular and Thoracic Surgery	27(6)	895-900	2018
Katada C, Horimatsu T, Muto M, Tanaka K, Matsuda K, Fujishiro M, Saito Y, Ohtsuka K, Oda I, Kato M, Kida M, Kobayashi K, Hoteya S, Kodashima S, Matsuda T, Yamamoto H, Ryozaawa S, Iwakiri R, Kutsumi H, <u>Miyata H</u> , Kato M, Haruma K, Fujimoto K, Uemura N, Kaminishi M, Tajiri H	Current status of esophageal endoscopy including the evaluation of smoking and alcohol consumption in Japan.	Esophagus	16(2)	174-179	2018
Kumamaru H, Lee M P, Choudhry N K, Dong YH, Krumme AA, Khan N, Brill G, Kohsaka S, <u>Miyata H</u> , Schneeweiss S, Gagne JJ	Using Previous Medication Adherence to Predict Future Adherence.	Journal of Managed Care & Specialty Pharmacy	24(11)	1146-1155	2018

Niikura R, Yamada A, Fujishiro M, Tanaka K, Matsuda K, Saito Y, Ohtsuka K, Oda I, Katada C, Kato M, Kida M, Kobayashi K, Hoteya S, Horimatsu T, Kodashima S, Matsuda T, Muto M, Yamamoto H, Ryozaawa S, Iwakiri R, Kutsumi H, <u>Miyata H</u> , Kato M, Haruma K, Fujimoto K, Uemura N, Kaminishi M, Shinozaki T, Tajiri H, Koike K	Propensity-matched analysis of a side-clamp versus an anastomosis assist device in cases of isolated coronary artery bypass grafting.	European Journal of Cardio-Thoracic Surgery	54(5)	889-895	2018
Kanaji S, Takahashi A, <u>Miyata H</u> , Marubashi S, Kakeji Y, Konno H, Gotoh M, Seto Y	Initial verification of data from a clinical database of gastroenterological surgery in Japan.	Surgery Today	49(4)	328-222	2018
Niikura R, Yamada A, Fujishiro M, Tanaka K, Matsuda K, Saito Y, Ohtsuka K, Oda I, Katada C, Kato M, Kida M, Kobayashi K, Hoteya S, Horimatsu T, Kodashima S, Matsuda T, Muto M, Yamamoto H, Ryozaawa S, Iwakiri R, Kutsumi H, <u>Miyata H</u> , Kato M, Haruma K, Fujimoto K, Uemura N, Kaminishi M, Shinozaki T, Tajiri H, Koike K	The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests, Digestion.	Digestion	8(1)	10	2018
Honda M, Kumamaru H, Etoh T, <u>Miyata H</u> , Yamashita Y, Yoshida K, Kodera Y, Kakeji Y, Inomata M, Konno H, Seto Y, Kitano S, Watanabe M, Hiki N	Surgical risk and benefits of laparoscopic surgery for elderly patients with gastric cancer: a multicenter prospective cohort study.	Gastric Cancer	[Epub]		2018
Iwatsuki M, Yamamoto H, <u>Miyata H</u> , Kakeji Y, Yoshida K, Konno H, Seto Y, Baba H	Effect of hospital and surgeon volume on postoperative outcomes after distal gastrectomy for gastric cancer based on data from 145,523 Japanese patients collected from a nationwide web-based data entry system.	Gastric Cancer	22(1)	190-201	2018

Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Shimada Y, Sato M, Toyooka S, Okada Y, Sato Y, Yoshino I, Okada M, Okumura M, Chida M, Fukuchi E, <u>Miyata H</u>	Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan.	General Thoracic and Cardiovascular Surgery	67(3)	297-305	2018
Ueki C, <u>Miyata H</u> , Motomura N, Sakata R, Sakaguchi G, Akimoto T, Takamoto S	Japan Cardiovascular Surgery Database. Off-pump technique reduces surgical mortality after elective coronary artery bypass grafting in patients with preoperative renal failure.	The Journal of Thoracic and Cardiovascular Surgery Home Page	156(3)	976-983	2018
Kuno T, Numasawa Y, Sawano M, Katsuki T, Kodaira M, Ueda I, Suzuki M, Noma S, Negishi K, Ishikawa S, <u>Miyata H</u> , Fukuda K, Kohsaka S	Effects of body habitus on contrast-induced acute kidney injury after percutaneous coronary intervention.	PLoS One	13(9)		2018
Hiraide T, Sawano M, Shiraishi Y, Ueda I, Numasawa Y, Noma S, Negishi K, Ohki T, Yuasa S, Hayashida K, <u>Miyata H</u> , Fukuda K, Kohsaka S	Impact of catheter-induced iatrogenic coronary artery dissection with or without postprocedural flow impairment: A report from a Japanese multicenter percutaneous coronary intervention registry.	PLoS One	13(9)		2018
Tomotaki A, Kumamaru H, Hashimoto H, Takahashi A, Ono M, Iwanaka T, <u>Miyata H</u>	Evaluating the quality of data from the Japanese National Clinical Database 2011 via a comparison with regional government report data and medical charts.	Surgery Today	49(1)	65-71	2018
Imamura M, Hirata K, Unno M, Kamiya K, Gotoh M, Konno H, Shibata A, Sugihara K, Takahashi A, Nishiyama M, Hakamada K, Fukui T, Furukawa T, Mizushima T, Mizuma M, <u>Miyata H</u> , Mori M, Takemasa I, Mizuguchi T, Fujiwara T	Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future.	International Journal of Clinical Oncology	24(2)	189-195	2018
Minakawa M, Fukuda I, <u>Miyata H</u> , Motomura N, Takamoto S, Taniguchi S, Daitoku	Japan Cardiovascular Surgery Database Organization. Outcomes of Pulmonary	Circulation Journal	82(8)	2184-2190	2018

K, Kondo N	Embolectomy for Acute Pulmonary Embolism.				
Handa N, Kumamaru H, Torikai K, Kohsaka S, Takayama M, Kobayashi J, Ogawa H, Shirato H, Ishii K, Koike K, Yokoyama Y, <u>Miyata H</u> , Motomura N, Sawam Y	Japanese TAVR Registry Participants, Learning Curve for Transcatheter Aortic Valve Implantation Under a Controlled Introduction System - Initial Analysis of a Japanese Nationwide Registry.	Circulation Journal	82(7)	1951-1958	2018
宮田哲郎, 遠藤将光, 東信良, 大木隆生, 古森公浩, 佐藤紀, 遠藤俊哉, 石田 敦久, 和泉裕一, 井上芳徳, 内田恒, 黒澤弘二, 児玉章朗, 駒井宏好, 重松邦広, 渋谷卓, 杉本郁夫, 出口順夫, 錦見尚道, 保科克行, 前田英明, 正木久男, 三井信介, 緑川博文, 山岡輝年, 山下裕也, 柚木靖弘, 高橋新, 宮田裕章	日本血管外科学会JCLIMB委員会、NCD JCLIMB分析チーム 2015年JAPAN Critical Limb Ischemia Database(JCLIMB)年次報告	日本血管外科学会雑誌	27(3)	155-158	2018
Mizushima T, Yamamoto H, Marubashi S, Kamiya K, Wakabayashi G, <u>Miyata H</u> , Seto Y, Doki Y, Mori M	Risk assessment of morbidities after right hemicolectomy based on the National Clinical Database in Japan.	Annals of Gastroenterological Surgery	2(3)	220-230	2018
臼井規朗, 岡本晋弥, 上原秀一郎, 小笠原有紀, 古賀寛之, 佐々木隆士, 寺脇幹, 照井慶太, 藤代準, 藤野明浩, 文野誠久, 古村眞, 平原憲道, 岡本竜弥, 富田紘史, 藤雄木亨真, 渡辺栄一郎, 米倉竹夫, 家入里志, 伊勢一哉, 佐々木英之, 下野隆一, 高安肇, 尾藤祐子, <u>宮田裕章</u> , 江角元史郎	日本小児外科学会NCD連絡委員会 National Clinical Database(小児外科領域)Annual Report 2013-2014	日本小児外科学会雑誌	51(4)	314-335	2018
Nakatsuka T, Soroida Y, Nakagawa H, Shindo T, Sato M, Soma K, Nakagomi R, Kobayashi T, Endo M, Hikita H, Sato M, Gotoh H, Iwai T, Yasui M, Shinozaki-Ushiku A, Shiraga K, Asakai	Identification of liver fibrosis using the hepatic vein waveform in patients with Fontan circulation.	Hepato Res	49(3)	304-313	2019

H, Hirata Y, Fukayama M, Ikeda H, Yatomi Y, <u>Tateishi R</u> , Inuzuka R, Koike K					
Nakagomi R, <u>Tateishi R</u> , Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment.	J Gastroenterol Hepatol	34(5)	921-928	2019
Wake T, <u>Tateishi R</u> , Nakagomi R, Fujiwara N, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Tanaka Y, Shiina S, Koike K	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery.	Hepatol Res	49(4)	453-461	2019
Uchino K, <u>Tateishi R</u> , Nakagomi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shibahara J, Shiina S, Koike K	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation.	PLoS One	13(7)	e0200943	2018
Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, <u>Tateishi R</u> , Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K	CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.	Gut	67(8)	1493-1504	2018
Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, <u>Tateishi R</u> , Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of J.	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort.	Ann Surg	[Epub]		2018

Tanaka Y, <u>Tateishi R</u> , Koike K	Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.	Int J Mol Sci	19(10)		2018
竹村信行、 <u>國土典宏</u> 、 <u>長谷川潔</u>	【肝癌診療ガイドライン2017改訂のポイント】外科側からの改訂ポイント	The Liver Cancer Journal	10(2)	105-109	2018